SEC Form 4 · accession 0000899243-16-032622
INFINITY PHARMACEUTICALS, INC. · INFI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Julian Adams
Officer — President of R&D
Period of report
Oct 31, 2016
Accepted (ET)
Nov 2, 2016 · 4:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001113148
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Oct 31, 2016 | A | 59,150 | $0.00 | A | 59,150 | D | |
| Common Stock | holding | — | — | — | 262,945 | I | Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares from a grant of performance-based restricted stock on July 22, 2016. Upon the determination by the Compensation Committee of our Board of Directors, such shares vested in full on October 31, 2016.
Remarks
Ex. 24: Limited Power of Attorney